Certis Oncology has announced the launch of its Certis Oncology Intelligence® Platform, an integrated system designed to advance cancer research by combining predictive and agentic artificial intelligence with biological validation.
The platform aims to address a critical challenge in oncology drug development: translating vast amounts of biological data into reliable predictions of therapeutic response. By integrating AI-driven modeling with functional biological validation in a closed-loop system, Certis intends to provide pharmaceutical and biotechnology companies with a tool to improve confidence in their translational and clinical decision-making processes, potentially accelerating the development of more effective cancer treatments.
What We Know So Far
- Certis Oncology announced the official launch of its new platform, named Certis Oncology Intelligence®, according to a press release distributed by Business Wire.
- The platform is engineered to generate data-driven insights by combining predictive modeling, agentic AI for data exploration, and functional biological validation.
- It operates as a secure, multi-tenant, closed-loop system that integrates three distinct data layers to create a comprehensive analytical environment.
- The stated goal is to assist pharmaceutical and biotech firms in enhancing the certainty of their decisions during the translational and clinical phases of drug development.
- A core component is the Predictive Intelligence Layer, CertisAI™, which is described as a patented, generalized drug-response foundation model, as reported by outlets including the Times Argus.
